{"id":"NCT01600014","sponsor":"LEO Pharma","briefTitle":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","officialTitle":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-05","primaryCompletion":"2014-02","completion":"2014-02","firstPosted":"2012-05-16","resultsPosted":"2016-05-09","lastUpdate":"2025-03-10"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"Ingenol mebutate gel, 0.015%","otherNames":[]},{"type":"DRUG","name":"Vehicle gel","otherNames":[]}],"arms":[{"label":"Ingenol mebutate gel, 0.015%","type":"ACTIVE_COMPARATOR"},{"label":"Vehicle gel","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.","primaryOutcome":{"measure":"Number of Participants With Complete Clearance of AKs 8 Weeks After Randomisation","timeFrame":"8 weeks after randomisation","effectByArm":[{"arm":"Ingenol Mebutate Gel, 0.015% Field Recalcitrant Subgroup","deltaMin":43,"sd":null},{"arm":"Vehicle Gel Field Recalcitrant Subgroup","deltaMin":9,"sd":null},{"arm":"Ingenol Mebutate Gel 0.015% Field Recurrent Subgroup","deltaMin":25,"sd":null},{"arm":"Vehicle Gel Field Recurrent Subgroup","deltaMin":5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"},{"comp":"OG002 vs OG003","p":"0.013"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":20},"locations":{"siteCount":13,"countries":["Australia","Canada","France","Germany","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.leopharmatrials.com/en"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":450},"commonTop":["Application site pain","Actinic keratosis","Basal cell carcinoma","Application site pruritus","Headache"]}}